Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2007

View Archived Issues

New Integrity Disease Briefing highlights head and neck cancers

Preclinical and phase I data on activity of AT-1001 presented

Satraplatin improves pain and PSA responses in phase III trial

Vardenafil studies presented at European Association of Urology congress

LY-2076962, non-morphinan opioid receptor antagonist, evaluated in phase I study

Celsion files for SPA for ThermoDox

MEDI-545 begins clinical evaluation in psoriasis

Novartis signs agreement for branded interferon beta-1b

New therapeutic agents for thrombotic disorders disclosed in recent patent literature

Ethics approval for second phase IIa neuropathic pain study of ACV-1

EvoGenix achieves milestone in GSK collaboration for protein-based therapeutics

Zanaflu registered as brand name for chitosan gel

Recent patents report novel analgesic agents

CHR-2797 begins phase II for AML in elderly patients

Semafore's PI3K inhibitor studied in phase I for solid tumors

Arrowhead Research forms new nanomedicine subsidiary

New agents for treating neurological disorders disclosed in recent patents

Merck & Co. and Schering-Plough to develop new cholesterol lowering product

PF-184298 presented as clinical candidate by Pfizer

Phase III study of vilazodone in depression completes enrollment

European orphan drug designation for enzastaurin in DLBCL

orBec cleared for phase II study in prevention of GVHD

New selective androgen receptor modulator profiled at Merck

BioLineRx in-licenses new therapeutic candidates

Positive phase IIa results for DIO-902 in type 2 diabetes

Cephalon files for European approval of fentanyl effervescent buccal tablet

Modiodal launched in Japan

AZ-004 reduces agitation in schizophrenic patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...